These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 6768154)

  • 1. Occurrence of soluble very high molecular weight fibrinogen complexes in hypercoagulable states. An in vitro and in vivo study on their features.
    Neri Serneri GG; Gensini GF; Abbate R; Favilla S
    Thromb Haemost; 1980 Feb; 42(5):1561-73. PubMed ID: 6768154
    [No Abstract]   [Full Text] [Related]  

  • 2. The clinical significance of fibrinogen degradation products.
    Bick RL
    Semin Thromb Hemost; 1982 Oct; 8(4):302-30. PubMed ID: 6758120
    [No Abstract]   [Full Text] [Related]  

  • 3. Soluble crosslinked fibrin(ogen) polymers.
    Selmayr E; Müller-Berghaus G
    Thromb Haemost; 1985 Dec; 54(4):804-7. PubMed ID: 4089815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A review of the basic mechanisms of fibrinogen to fibrin conversion and of fibrinolysis: intravascular coagulation versus primary fibrinolysis.
    Colick JA; Fisher LM
    Va Med Mon (1918); 1970 May; 97(5):310-4 passimass. PubMed ID: 4276992
    [No Abstract]   [Full Text] [Related]  

  • 5. [A novel molecular marker for thrombus formation and life prognosis--clinical usefulness of measurement of soluble fibrin monomer-fibrinogen complex (SF)].
    Koga S
    Rinsho Byori; 2004 Apr; 52(4):355-61. PubMed ID: 15164605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alterations in the coagulation and fibrinolysis system in pregnancy, labour and puerperium, with special reference to a possible transitory state of intravascular coagulation during labour.
    Gilabert J; Aznar J; Parrilla JJ; Regañon E; Vila V; Estelles A
    Thromb Haemost; 1978 Oct; 40(2):387-96. PubMed ID: 104402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibrin detected in plasma of patients with disseminated intravascular coagulation by fibrin-specific antibodies consists primarily of high molecular weight factor XIIIa-crosslinked and plasmin-modified complexes partially containing fibrinopeptide A.
    Pfitzner SA; Dempfle CE; Matsuda M; Heene DL
    Thromb Haemost; 1997 Sep; 78(3):1069-78. PubMed ID: 9308756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Properties of soluble fibrin polymers encountered in thrombotic states.
    Bang NU; Hansen MS; Smith GF; Mosesson MW
    Thromb Diath Haemorrh Suppl; 1973; 56():75-90. PubMed ID: 4218377
    [No Abstract]   [Full Text] [Related]  

  • 9. Soluble fibrin complexes and fibrinogen heterogeneity in diabetes mellitus.
    Tsianos EB; Stathakis NE
    Thromb Haemost; 1980 Dec; 44(3):130-4. PubMed ID: 6162208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progress in the measurement of circulating fibrinogen derivatives.
    Wilner GD
    Prog Clin Pathol; 1984; 9():15-45. PubMed ID: 6229812
    [No Abstract]   [Full Text] [Related]  

  • 11. [Relationship between the plasma levels of soluble fibrin monomer and the formation of soluble fibrin monomer complex (SFMC)].
    Okajima K; Okabe H; Kumagai T; Yang WP; Maeda M; Miyagawa S; Watanabe E; Yoshimi K; Koga S; Takatsuki K
    Rinsho Byori; 1989 Apr; 37(4):411-5. PubMed ID: 2787429
    [No Abstract]   [Full Text] [Related]  

  • 12. The use of soluble fibrin in evaluating the acute and chronic hypercoagulable state.
    Dempfle CE
    Thromb Haemost; 1999 Aug; 82(2):673-83. PubMed ID: 10605767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of fibrinogen derivatives in plasma samples.
    Graeff H; von Hugo R
    Thromb Diath Haemorrh; 1972 Jul; 27(3):610-8. PubMed ID: 4197047
    [No Abstract]   [Full Text] [Related]  

  • 14. [In-vivo studies on the elimination of various soluble fibrin-preparations].
    Mahn I; von Drach H; Müller-Berghaus G
    Verh Dtsch Ges Inn Med; 1976; 82 Pt 2():1643-6. PubMed ID: 1030067
    [No Abstract]   [Full Text] [Related]  

  • 15. [Molecular marker for detecting hypercoagulable state].
    Magari Y; Mizunaga S; Ito M; Shibata T; Ito H
    Rinsho Byori; 1994 Jan; 42(1):22-33. PubMed ID: 8107279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancement of blood coagulation by soluble fibrin complexes.
    Hansen MS; Bang NU; Barton RD; Mattler LE
    J Exp Med; 1975 May; 141(5):944-61. PubMed ID: 805207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effect of heparin on fibrinogen formation during experimental toxic syndrome of disseminated intravascular coagulation].
    Barkagan ZS; Momot AP; Glazunova GA; Taranina TS; Koltakova SI
    Ukr Biokhim Zh (1978); 1988; 60(1):23-9. PubMed ID: 3363673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterisation of serum fibrinogen degradation products using gel chromatography and radioimmunoassay.
    Ratky SM; Sykes A; Cooke ED; Gordon YB
    Thromb Haemost; 1977 Jun; 37(3):471-6. PubMed ID: 578027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A study of soluble fibrin monomer complexes (SFMC) and plasma fibrinogen in acute myocardial infarction.
    Jain SM; Trivedi S
    Indian J Chest Dis Allied Sci; 1984; 26(2):98-103. PubMed ID: 6530267
    [No Abstract]   [Full Text] [Related]  

  • 20. [Studies on fibrinogen heterogeneity in disseminated intravascular coagulation].
    Yamauchi M
    Hokkaido Igaku Zasshi; 1982 Jul; 57(4):425-36. PubMed ID: 7173813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.